杜尔瓦卢马布巩固疗法期间的肺炎影响NSCLC第三阶段的存活率
Yuhei Kinehara1, Takayuki Shiroyama2, Akihiro Tamiya3
1Department of Respiratory Medicine and Clinical Immunology, Nippon Life Hospital, Osaka, Japan.
JTO clinical and research reports
|November 29, 2023
概括
在治疗第三阶段NSCLC的化学放射治疗后接受杜尔瓦卢马布的患者中,严重的肺炎与更差的存活率有关. 状组织学也表明这个患者群体的预后较差.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 肺部病理学 肺部病理学
背景情况:
- 杜尔瓦卢马布整合疗法是第三阶段NSCLC后同步化疗放射治疗 (CRT) 的标准.
- 免疫相关性肺炎 (IRP) 是杜尔瓦卢马布的严重副作用,但其对生存的影响尚未确定.
- 本研究研究了肺部和非肺部免疫相关不良事件 (irAEs) 对杜尔瓦卢马布在第三阶段NSCLC中的疗效的影响.
研究的目的:
- 调查肺炎和其他irrAEs对使用杜尔瓦卢马布巩固疗法治疗III期NSCLC患者的生存结果的影响.
- 为了确定与CRT后接受杜尔瓦卢马布的患者的生存相关的预后因素.
主要方法:
- 对158名在CRT后接受杜尔瓦卢马布治疗的3期NSCLC患者的回顾性分析.
- 肺炎患者与其他irrAEs患者之间的生存结果的比较.
- 排除3个月生存率的患者,以减轻不朽时间偏差.
主要成果:
- 52%的患者经历了等级≥2的IRAE.
- 患有≥2级肺炎 (n=55) 的患者的整体存活率明显低于患有≥2级非肺炎的患者 (n=27).
- 多变量分析确定了≥2级肺炎 (HR=3.71) 和状组织学 (HR=2.64) 作为较差整体存活率的独立预测因素.
结论:
- 2级以上的肺炎是治疗杜尔瓦卢马布巩固治疗的第三阶段NSCLC患者整体存活期的显著不良预后因素.
- 状组织学也独立地与更糟糕的生存结果有关.
- 这些发现强调了肺炎严重程度对治疗疗效和患者预后的关键影响.
更多相关视频
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
10.6K
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
5.0K
相关概念视频
01:30Pneumonia III: Complications and Assessment
239
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
239
01:28Pneumonia IV: Management
333
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
333
01:30Pneumonia V: Nursing management and Prevention
2.1K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
2.1K
01:26COPD: Management Using Bronchodilators and Corticosteroids
214
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
214
01:27Pneumothorax-II
160
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
160
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K